<strong>Society</strong> <strong>of</strong> <strong>Toxicology</strong> 2012 Continuing Education diverse universe <strong>of</strong> mixtures, including those found in air, water, soil, and food, and apply to environmental, industrial, pharmaceutical, intentional, and accidental mixtures. The course will be useful to toxicologists as understanding how their data are used to assess risk will enable the design and conduct <strong>of</strong> more meaningful and useful multipollutant experiments. Additionally, understanding underlying assumptions will foster design and conduct <strong>of</strong> experiments to replace assumptions with evidence-based understanding. • Risk Assessment Methods for Whole Mixtures. Jane Ellen Simmons, US EPA, Research Triangle Park, NC. • Beyond Relative Potencies: Uncertainties in the Application <strong>of</strong> TEFs in Risk Assessment. Michael J. DeVito, NIEHS, Research Triangle Park, NC. • Using Dose Addition: Hazard Index, Target Organ Toxicity Hazard Index, and the Interaction-Weighted Hazard Index. Richard C. Hertzberg, Biomathematics Consulting, Atlanta, GA. • The Use <strong>of</strong> Binary Weight <strong>of</strong> Evidence to Characterize Chemical Interactions for Risk Assessment. Moiz Mumtaz, ATSDR, Atlanta, GA. Drug Metabolism The Use <strong>of</strong> Physiologically-Based Pharmacokinetic Modeling to Inform Early Life Sensitivity to Chemical Toxicity The presentations will provide an overview <strong>of</strong> pharmacokinetic factors affecting early life sensitivity and two case studies <strong>of</strong> PBPK approaches for gestation/lactation and childhood exposures, plus a demonstration <strong>of</strong> how PBPK modeling <strong>of</strong> development can be used to evaluate neonatal epidemiological results. The course participants will get in-depth understanding <strong>of</strong> the value <strong>of</strong> PBPK modeling in addressing issues <strong>of</strong> potential sensitivity in infants and children and the possible application scenarios <strong>of</strong> this valuable tool. • Physiological and Pharmacokinetic Factors Affecting Early Life Sensitivity to Chemical Exposures. Rebecca A. Clewell, The Hamner Institutes for Health Sciences, Research Triangle Park, NC. • PBPK Modeling <strong>of</strong> Manganese Exposures during Gestation and Lactation. Miyoung Yoon, The Hamner Institutes for Health Sciences, Research Triangle Park, NC. • Modeling <strong>of</strong> Pyrethroid Exposures in Early Life. Rogelio Tornero- Velez. US EPA, Research Triangle Park, NC. • Use <strong>of</strong> PBPK Models <strong>of</strong> Perfluorinated Compounds to Evaluate Whether Epidemiologic Associations Are Due to Reverse Causality. Matthew P. Longnecker, NIEHS, Research Triangle Park, NC. PM13 CE Advanced CE Chairperson(s): Harvey J. Clewell, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, and Miyoung Yoon, The Hamner Institutes for Health Sciences, Research Triangle Park, NC. Endorsed by: Regulatory and Safety Evaluation Specialty Section A major challenge in assessing potential susceptibility to environmental chemicals during in utero and postnatal development is uncertainty regarding the actual exposure in the target subpopulation. We will demonstrate the value <strong>of</strong> PBPK modeling in quantitative health risk assessments for infants and children by providing a scientifically sound tool to predict the target tissue dose in the young. A thorough understanding <strong>of</strong> dynamic changes in physiological and biochemical factors is essential to predict the target tissue exposure during development. Factors that influence the kinetic behavior <strong>of</strong> chemicals in early life include ontogeny in metabolizing enzymes, changes in transporter expression, maturation <strong>of</strong> biological barriers such as the blood brain barrier, differential growth <strong>of</strong> tissues, and distinct exposure patterns compared to adults. PBPK modeling provides a means to integrate these factors in the proper context and thus reduce uncertainty in conducting risk/safety assessment for early life. Thematic Session 60 SOT’s 51 st <strong>Annual</strong> <strong>Meeting</strong>
Notes up-to-date information at www.toxicology.org 61
- Page 1 and 2:
SOT | Program Preliminary Program S
- Page 3 and 4:
Preliminary Program Contents Prelim
- Page 5 and 6:
Preliminary Program Overview Sectio
- Page 7 and 8:
Monday, March 12 8:00 AM-9:00 AM PL
- Page 9 and 10:
9:00 AM-12:30 PM Poster Sessions
- Page 11 and 12: Clinical Toxicology from Bedside to
- Page 13 and 14: San Francisco, California SOT San F
- Page 15 and 16: 51 st Annual Meeting and ToxExpo Ge
- Page 17 and 18: 51 st Annual Meeting and ToxExpo Ge
- Page 19 and 20: 51 st Annual Meeting and ToxExpo Ge
- Page 21 and 22: 51 st Annual Meeting and ToxExpo Ge
- Page 23 and 24: 51 st Annual Meeting and ToxExpo Ge
- Page 25 and 26: 51 st Annual Meeting and ToxExpo Ge
- Page 27 and 28: 51 st Annual Meeting and ToxExpo Ge
- Page 29 and 30: 51 st Annual Meeting and ToxExpo Ge
- Page 31 and 32: 51 st Annual Meeting and ToxExpo Ge
- Page 33 and 34: (Required: Please check the appropr
- Page 35 and 36: Registration Form SOT 51 st Annual
- Page 37 and 38: Scientific Posters SNACK BAR 016 11
- Page 39 and 40: 51 st Annual Meeting and ToxExpo Ca
- Page 41 and 42: Congratulations! Society of Toxicol
- Page 43 and 44: San Francisco, California Special E
- Page 45 and 46: San Francisco, California Special E
- Page 47 and 48: San Francisco, California Special E
- Page 49 and 50: Congratulations on the Increased Im
- Page 51 and 52: San Francisco, California Special E
- Page 53 and 54: Council and Annual Meeting Organizi
- Page 55 and 56: 51 st Annual Meeting and ToxExpo Co
- Page 57 and 58: 51 st Annual Meeting and ToxExpo Co
- Page 59 and 60: 51 st Annual Meeting and ToxExpo Co
- Page 61: 51 st Annual Meeting and ToxExpo Co
- Page 65 and 66: 51 st Annual Meeting and ToxExpo Th
- Page 67 and 68: 51 st Annual Meeting and ToxExpo Th
- Page 69 and 70: Notes up-to-date information at www
- Page 71 and 72: San Francisco, California The Thema
- Page 73 and 74: San Francisco, California The Thema
- Page 75 and 76: San Francisco, California The Thema
- Page 77 and 78: San Francisco, California The Thema
- Page 79 and 80: San Francisco, California The Thema
- Page 81 and 82: San Francisco, California The Thema
- Page 83 and 84: San Francisco, California The Thema
- Page 85 and 86: San Francisco, California The Thema
- Page 87 and 88: San Francisco SOT 2012 Submit Your
- Page 89 and 90: 51 st Annual Meeting and ToxExpo Th
- Page 91 and 92: 51 st Annual Meeting and ToxExpo Th
- Page 93 and 94: 51 st Annual Meeting and ToxExpo Th
- Page 95 and 96: 51 st Annual Meeting and ToxExpo Th
- Page 97 and 98: 51 st Annual Meeting and ToxExpo Th
- Page 99 and 100: 51 st Annual Meeting and ToxExpo Th
- Page 101 and 102: 51 st Annual Meeting and ToxExpo Th
- Page 103 and 104: San Francisco, California The Thema
- Page 105 and 106: San Francisco, California The Thema
- Page 107 and 108: 51 st Annual Meeting and ToxExpo Th
- Page 109 and 110: 51 st Annual Meeting and ToxExpo Th
- Page 111 and 112: San Francisco, California The Thema
- Page 113 and 114:
51 st Annual Meeting and ToxExpo Th
- Page 115 and 116:
SOT If your company is interested i
- Page 117 and 118:
It all adds up to an uncommonly ric
- Page 119 and 120:
up-to-date information at www.toxic
- Page 121 and 122:
San Francisco, California Exhibitor
- Page 123 and 124:
Notes up-to-date information at www
- Page 125 and 126:
Notes up-to-date information at www
- Page 127 and 128:
Notes up-to-date information at www
- Page 129 and 130:
52 nd Annual Meeting & ToxExpo 52 n
- Page 131 and 132:
Appreciates the Generous 51st Annua